These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Magbanua MJ; Sosa EV; Roy R; Eisenbud LE; Scott JH; Olshen A; Pinkel D; Rugo HS; Park JW Cancer Res; 2013 Jan; 73(1):30-40. PubMed ID: 23135909 [TBL] [Abstract][Full Text] [Related]
24. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. Ramirez AB; Bhat R; Sahay D; De Angelis C; Thangavel H; Hedayatpour S; Dobrolecki LE; Nardone A; Giuliano M; Nagi C; Rimawi M; Osborne CK; Lewis MT; Stilwell JL; Kaldjian EP; Schiff R; Trivedi MV BMC Cancer; 2019 Mar; 19(1):220. PubMed ID: 30871481 [TBL] [Abstract][Full Text] [Related]
25. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837 [TBL] [Abstract][Full Text] [Related]
26. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Fernandez SV; Bingham C; Fittipaldi P; Austin L; Palazzo J; Palmer G; Alpaugh K; Cristofanilli M Breast Cancer Res; 2014 Oct; 16(5):445. PubMed ID: 25307991 [TBL] [Abstract][Full Text] [Related]
27. HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques. Brouwer A; De Laere B; van Dam PJ; Peeters D; Van Haver J; Sluydts E; El Moussaoui A; Mendelaar P; Kraan J; Peeters M; Van Laere S; Dirix L PLoS One; 2019; 14(9):e0220906. PubMed ID: 31483799 [TBL] [Abstract][Full Text] [Related]
28. Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. D'Oronzo S; Lovero D; Palmirotta R; Stucci LS; Tucci M; Felici C; Cascardi E; Giardina C; Cafforio P; Silvestris F Sci Rep; 2019 Nov; 9(1):17276. PubMed ID: 31754145 [TBL] [Abstract][Full Text] [Related]
29. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. Paoletti C; Cani AK; Larios JM; Hovelson DH; Aung K; Darga EP; Cannell EM; Baratta PJ; Liu CJ; Chu D; Yazdani M; Blevins AR; Sero V; Tokudome N; Thomas DG; Gersch C; Schott AF; Wu YM; Lonigro R; Robinson DR; Chinnaiyan AM; Bischoff FZ; Johnson MD; Park BH; Hayes DF; Rae JM; Tomlins SA Cancer Res; 2018 Feb; 78(4):1110-1122. PubMed ID: 29233927 [TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. Babayan A; Hannemann J; Spötter J; Müller V; Pantel K; Joosse SA PLoS One; 2013; 8(9):e75038. PubMed ID: 24058649 [TBL] [Abstract][Full Text] [Related]
32. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Heitzer E; Auer M; Gasch C; Pichler M; Ulz P; Hoffmann EM; Lax S; Waldispuehl-Geigl J; Mauermann O; Lackner C; Höfler G; Eisner F; Sill H; Samonigg H; Pantel K; Riethdorf S; Bauernhofer T; Geigl JB; Speicher MR Cancer Res; 2013 May; 73(10):2965-75. PubMed ID: 23471846 [TBL] [Abstract][Full Text] [Related]
33. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing. Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061 [TBL] [Abstract][Full Text] [Related]
34. Comparative genomic analysis of primary tumors and metastases in breast cancer. Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851 [TBL] [Abstract][Full Text] [Related]
35. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test. Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318 [TBL] [Abstract][Full Text] [Related]
36. Optimization of a WGA-Free Molecular Tagging-Based NGS Protocol for CTCs Mutational Profiling. De Luca G; Cardinali B; Del Mastro L; Lastraioli S; Carli F; Ferrarini M; Calin GA; Garuti A; Mazzitelli C; Zupo S; Dono M Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575430 [TBL] [Abstract][Full Text] [Related]
37. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222 [TBL] [Abstract][Full Text] [Related]